← Leaderboards
Stephane Angers
University Of Minnesota
$1,341,861
Attributed
$3,093,399
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $739.2K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,093,399 · 2
By mechanism
R01$3,093,399 · 2
Top collaborators
- Harald Junge5 shared
- Shana O Kelley5 shared
- Jason Moffat5 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Harald Junge$5,205,817
- Edgar A Arriaga$9,497,757
- Mark D Distefano$11,695,253
Others in their field
Other Emerging Leaders on “Pathway Interactions”
- April Brinkoetter · Hungry Heart Media, Inc.$59,802,265
- Kevin Urdahl · Seattle Children'S Hospital$47,227,116
- Urs Ochsner · Crestone, Inc.$38,569,476
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Nader Fotouhi · Global Alliance For Tb Drug Development$28,468,137
- Jeffrey Glenn · Stanford University$26,017,226
Research focus
Pathway InteractionsFunctional DisorderSignal TransductionNovel TherapeuticsCellsAntibodiesBiologicalProteinsGenesProliferatingBloodBevacizumabActive Biological TransportBlood-Retinal BarrierCell Surface Proteins3d PrintCancer TypeBenchmarkingCell SeparationCd47 GeneBeta CateninCell FixationCell LineCancer Therapy
Grant awards (10)
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models$453,631
R01 · FY2025 · EY
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$239,392
R01 · FY2025 · CA
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models$453,631
R01 · FY2024 · EY
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$249,479
R01 · FY2024 · CA
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models$36,094
R01 · FY2024 · EY
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models$453,631
R01 · FY2023 · EY
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$259,550
R01 · FY2023 · CA
Investigation of a first-in-class Frizzled4/LRP5 agonist in retinal disease models$467,381
R01 · FY2022 · EY
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$268,031
R01 · FY2022 · CA
Development of microfluidic enabled CRISPR-Cas9 functional genetic screening technologies for target discovery in cancer immunotherapy$212,579
R01 · FY2021 · CA